The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Cell Reprogramming (iPSC Generation) / Direct Reprogramming Services and Products Market, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    March 2020

  • Pages
    293

  • View Count
    929

Example Insights

Cell-Reprogramming-Context Cell-Reprogramming-Service-Providers Cell-Reprogramming-Types-of-cells
Cell-Reprogramming-Distribution-by-location Cell-Reprogramming-Competitiveness-analysis Cell-Reprogramming-Partnerships-and-collaborations
Cell-Reprogramming-Case-study Cell-Reprogramming-Strategic-partners Cell-Reprogramming-Market-forecast

 

Overview

Over the years, advances in stem cell biology and regenerative medicine have enabled the discovery and development of a number of stem cell-based therapies. In fact, many believe that such interventions possess the potential to address several unmet needs related to the treatment of a wide range of diseases. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, effectively reversing the adverse physiological effects they cause. However, challenges, such as scarcity of healthy stem cell donors, adverse immunological reactions upon treatment (owing to donor-recipient haplotype mismatches), and a number of ethical concerns related to the use of stem cells, are impeding progress in this field. 

The discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka’s team in 2006 revolutionized stem cell research. Through his Nobel prize winning research, Yamanaka was able to reprogram mature somatic cells into a stem-like (pluripotent) state. This finding not only established the means to synthesize stem cells (thereby, offering a virtually endless supply of research material), but also provided the means to alleviate the social stigma surrounding stem cell research. Presently, cellular reprogramming is perceived as a powerful and versatile tool, with numerous applications in fundamental research and medicine. It is worth mentioning that, today, many experts believe that stem cell therapies may be a possible solution to the COVID-19 pandemic. In fact, there are speculations, based on some evidence, that infected patients treated with stem cells may be more likely to successfully combat the symptoms of the disease. Research has also demonstrated that mesenchymal stem cells have the potential to be effectively used to treat SARS-CoV-2 induced pneumonia. Numerous partnerships have been inked amongst stakeholders in this domain, indicative to future growth of the market. Interestingly, start-ups / university spin-offs have been the flagbearers in this upcoming field of therapeutics and are also expected to sustain the research momentum, over the coming years.

Scope of the Report

The ‘Cell Reprogramming (iPSC Generation) / Direct Reprogramming Services and Products Market, 2020-2030’ report features an extensive study of the current market landscape and the future potential of cell reprogramming services and products in treating different chronic conditions. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: 

  • A review of the overall landscape of cell reprogramming market, featuring a list of over 30 cell reprogramming (iPSC Generation) / direct reprogramming service and product providers and a detailed analysis of these providers based on a number of parameters, such as year of establishment, company size, geographical location, location of manufacturing facilities, type of  service (iPSC generation and direct reprogramming), type of offering (in-house development, kit, service, technology (for licensing) and iPSC lines), type of technology (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), type of vector used (viral vector, non-viral vector, mRNA and others), source cell for iPSC generation (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), target indication(s), type of application (research and therapeutic) and additional service(s) offered (assay development, cell and tissue sourcing, cell banking, cell characterization, cell differentiation, cell sequencing, genome editing and other services).  
  • An insightful competitiveness analysis of iPSC generation and direct reprogramming service providers, based on supplier strength (based on a company’s employee count and years of experience) and service strength (which takes into account the number of reprogramming technologies offered, number of source cells used for iPSC generation used, number of target indications and number of manufacturing facilities).
  • Elaborate profiles of the industry players that offer cell reprogramming services and products. Each profiles features a brief overview of the company, its financial information (if available), details on cell reprogramming approaches, types of cell(s) utilized and differentiated, target indication(s), other drug discovery services offered, recent developments and an informed future outlook. 
  • A detailed analysis of more than 540 completed, ongoing and planned clinical studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, study design, current trial status, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials.
  • An analysis of the partnerships that have been established in this domain since 2016, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, clinical trial agreements, process development agreements, and other relevant deals.
  • A list of stem cell therapy developers / manufacturers, generated based on a detailed analysis of a set of relevant parameters (such as company size (employee count), type of cell (s), indication count and existing partnership(s)), which are anticipated to partner with cell reprogramming service and product providers in the foreseen future.  

One of the key objectives of the report was to understand the primary growth drivers and the future opportunity in cell reprogramming (iPSC generation)/ direct reprogramming services and products market. Based on multiple parameters, such as growth of the overall iPSC market, reprogramming cost and annual number of projects for stem cell therapies, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period, 2020-2030. The report also features the likely distribution of the current and forecasted opportunity within cell reprogramming services and products market across [A] type of technology offered (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), [B] Source cells for iPSC generation  (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), [C] type of application (research and therapeutic), and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). To account for the uncertainties associated with the development of reprogrammed cells and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Christiana Pires (Co-Founder and Chief Executive Officer, Asgard Therapeutics)
  • Julien Maruotti (Chief Scientific Officer, Phenocell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured in our research. It offers a high-level view on the current state of cell reprogramming (iPSC generation) / direct reprogramming service and products market and their likely evolution in the short-mid term and long term. 

Chapter 3 provides a general overview of stem cell-based therapies, their classification and applications. In addition, it features a detailed discussion on cell reprogramming, including information on different cell reprogramming services. It provides information on the various cell reprogramming technologies available for the generation of iPSCs and their potential usability across different application areas. Further, the chapter includes a discussion on the key growth drivers and roadblocks to cell reprogramming.

Chapter 4 provides a review of the global cell reprogramming services and products market landscape. It includes information related to more than 30 players that are currently active in this domain. In addition, it features a detailed analysis of players based on the parameters, such as type of  service, type of offering, type of technology offered, type of vector used, source cell for iPSC generation, target indication(s), type of application and type of additional service(s) offered. The chapter also highlights the academic players that provide stem cell reprogramming services and products. Furthermore, we have presented the contributions of various stakeholders that are developing affiliated products required for cell reprogramming.

Chapter 5 features an insightful competitiveness analysis of both iPSC generation and direct reprogramming service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (based on a company’s employee count and years of experience) and service strength (which takes into account the number of reprogramming technologies offered, number of source cells used for iPSC generation, number of target indications and number of manufacturing facilities).

Chapter 6 provides elaborate profiles of all industry players that are currently engaged in the cell reprogramming domain. Each profile features a brief overview of the company, its financial information (if available), details on cell reprogramming approaches, types of cell(s) utilized and differentiated, target indication(s), other drug discovery services offered, recent developments and an informed future outlook. 

Chapter 7 features a detailed analysis of the partnerships / collaborations that have been inked amongst the players in this market. It includes a brief description on the various types of partnership models (such as product development / commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers / acquisitions, and others) that have been adopted by stakeholders in this domain, and analysis on the trend of partnerships inked since 2016. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to cell reprogramming. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 8 provides a detailed analysis of more than 540 completed, ongoing and planned clinical studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, study design, current trial status, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials

Chapter 9 presents a list of stem cell therapy developers / manufacturers that are anticipated to partner with cell reprogramming service and product providers in the foreseen future. The list was prepared based on an in-depth analysis of potential stakeholders, taking into consideration multiple parameters, such as company size (employee count), type of cell (s), indication count and existing partnership(s).

Chapter 10 presents an insightful market forecast analysis, highlighting the likely growth of the cell reprogramming (iPSC generation) / direct reprogramming services and products market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of technology offered (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), [B] Source cell for iPSC generation (fibroblast, blood mononuclear cells, unspecified somatic cells and other cells), [C] type of application (research and therapeutic), and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world).

Chapter 11 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Christiana Pires (Co-Founder and Chief Executive Officer, Asgard Therapeutics) and Julien Maruotti (Chief Scientific Officer, Phenocell).

Chapter 12 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Stem Cells
3.2.1. Classification of Stem Cells
3.2.1.1. Based on Source of Stem Cell
3.2.1.2. Based on Origin of Stem Cell
3.2.1.3. Based on Potency of Stem Cell
3.2.2. Routes of Administration of Stem Cell Therapies
3.2.3. Applications of Stem Cell Therapies

3.3. Introduction to Cell Reprogramming
3.3.1. Cell Reprogramming Approaches and Affiliated Technologies

3.4. Applications of Cell Reprogramming
3.5. Key Growth Drivers and Constraints

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell Reprogramming Service and Product Providers: List of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geographical Location
4.2.4. Analysis by Location of Manufacturing Facilities
4.2.5. Analysis by Type of Service
4.2.6. Analysis by Type of Offering
4.2.7. Analysis by Type of Technology
4.2.8. Analysis by Vector Used
4.2.9. Analysis by Source Cell for iPSC Generation
4.2.10. Analysis by Target Indication
4.2.11. Analysis by Application
4.2.12. Analysis by Additional Service(s) Offered

4.3. Cell Reprogramming Service and Product Providers: List of Non-Industry Players
4.3.1. Analysis by Geographical Location
4.3.2. Analysis by Type of Technology Used
4.3.3. Analysis by Type of Vector Used
4.3.4. Analysis by Source Cell for iPSC Generation

4.3. Cell Reprogramming: List of Affiliated Products Providers

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Competitiveness Analysis: iPSC Generation Service and Product Providers
5.5. Competitiveness Analysis: Direct Reprogramming Service and Product Providers

6. COMPANY PROFILES
6.1. Chapter Overview

6.2. Allele Biotechnology
6.2.1. Company Overview
6.2.2. Recent Developments and Future Outlook

6.3. ALSTEM
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook

6.4. Applied Biological Materials
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook

6.5. Axol Bioscience
6.5.1. Company Overview
6.5.2. Recent Developments and Future Outlook

6.6. Creative Bioarray
6.6.1. Company Overview
6.6.1.1. Recent Developments and Future Outlook

6.7. DefiniGEN
6.7.1. Company Overview
6.7.2. Recent Developments and Future Outlook

6.8. FUJIFILM Cellular Dynamics International
6.8.1. Company Overview
6.8.2. Recent Developments and Future Outlook

6.9. Lonza
6.9.1. Company Overview
6.9.2. Recent Developments and Future Outlook

6.10. Mogrify
6.10.1. Company Overview
6.10.2. Recent Developments and Future Outlook

6.11. REPROCELL
6.11.1. Company Overview
6.11.1.1. Recent Developments and Future Outlook

6.12. Stemnovate
6.12.1. Company Overview
6.12.2. Recent Developments and Future Outlook

6.14. Thermo fisher Scientific
6.14.1. Company Overview
6.14.1.1. Recent Developments and Future Outlook

7. CASE STUDY: CLINICAL TRIAL ACTIVITY IN STEM CELL THERAPY DEVELOPMENT
7.1. Chapter Overview
7.2. Scope and Methodology

7.3. Stem Cell Therapies: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Number of Patients Enrolled by Trial Registration Year
7.3.4. Analysis by Study Design
7.3.5. Analysis by Trial Recruitment Status
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Industry Sponsors: Analysis by Number of Registered Trials
7.3.8. Analysis by Trial Focus
7.3.9. Analysis by Type of Stem Cell
7.3.10. Analysis by Therapeutic Area
7.3.11. Analysis by Type of Stem Cell and Therapeutic Area
7.3.12. Geographical Analysis by Number of Clinical Trials
7.3.13. Geographical Analysis by Trial Recruitment Status
7.3.14. Geographical Analysis by Enrolled Patient Population

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Cell Reprogramming Services and Products Market: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partner
8.3.4. Analysis by Type of Partnership and Type of Partner
8.3.5. Analysis by Type of Stem Cell
8.3.6. Analysis by Target Therapeutic Area
8.3.7. Analysis by Application
8.3.8. Most Active Players: Analysis by Number of Partnerships
8.3.9. Regional Analysis
8.3.10. Intercontinental and Intracontinental Agreements

9. LIKELY PARTNERSHIP OPPORTUNITIES
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Scoring Criteria and Key Assumptions
9.4. Stem Cell Therapy Developers: Likely Partners for Cell Reprogramming Service and Product Providers
9.4.1. Likely Partners for Cell Reprogramming Service and Product Providers in North America
9.4.2. Likely Partners for Cell Reprogramming Service and Product Providers in Europe
9.4.3. Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World

9.5. Stem Cell Therapy Contract Manufacturers: Likely Partners for Cell Reprogramming Service and Product Providers
9.5.1. Likely Partners for Cell Reprogramming Service and Product Providers in North America
9.5.2. Likely Partners for Cell Reprogramming Service and Product Providers in Europe
9.5.3. Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World

10. MARKET FORECAST
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Forecast Methodology and Key Assumptions
10.4. Global Cell Reprogramming Services and Products Market, 2020-2030
10.4.1. Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, 2020-2030
10.4.1.1. Cell Reprogramming Services and Products Market for Episomal Reprogramming, 2020-2030
10.4.1.2. Cell Reprogramming Services and Products Market for mRNA Reprogramming, 2020-2030
10.4.1.3. Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, 2020-2030
10.4.1.4. Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, 2020-2030

10.4.2. Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, 2020-2030
10.4.2.1. Cell Reprogramming Services and Products Market for Fibroblasts, 2020-2030
10.4.2.2. Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, 2020-2030
10.4.2.3. Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, 2020-2030
10.4.2.4. Cell Reprogramming Services and Products Market for Other Cells, 2020-2030

10.4.3. Global Cell Reprogramming Services and Products Market: Distribution by Application, 2020-2030
10.4.3.1. Cell Reprogramming Services and Products Market for Research, 2020-2030
10.4.3.2. Cell Reprogramming Services and Products Market for Therapeutic Use, 2020-2030

10.4.4. Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, 2020-2030
10.4.4.1. Cell Reprogramming Services and Products Market in North America, 2020-2030
10.4.4.2. Cell Reprogramming Services and Products Market in Europe, 2020-2030
10.4.4.3. Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, 2020-2030

11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Asgard Therapeutics
11.2.1. Company Snapshot
11.2.2. Christiana Pires, Co-Founder and Chief Executive Officer

11.3. Phenocell
11.3.1. Company Snapshot
11.3.2. Interview Transcript: Julien Maruotti, Chief Scientific Officer

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Cellular Lineages used for Isolation of Stem Cells
Figure 3.2 Steps Involved in the Development and Administration of Stem Cells
Figure 3.3 Classification of Stem Cells
Figure 3.4 Classification based on Source of Stem Cell
Figure 3.5 Differences between Allogeneic and Autologous Stem Cell Therapies
Figure 3.6 Classification of Stem Cells based on Origin
Figure 3.7 Classification of Adult Stem Cells
Figure 3.8 Classification based on Potency of Stem Cell
Figure 3.9 Key Application Areas for Stem Cell Therapies
Figure 3.10 Potential Applications of Cell Reprogramming
Figure 3.11 Key Growth Drivers and Constraints to Cell Reprogramming
Figure 4.1 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Year of Establishment
Figure 4.2 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Company Size
Figure 4.3 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Geographical Location
Figure 4.4 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Location of Manufacturing Facilities
Figure 4.5 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Service
Figure 4.6 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Offering
Figure 4.7 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology
Figure 4.8 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology and Year of Establishment
Figure 4.9 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Vector Used
Figure 4.10 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation
Figure 4.11 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation and Company size
Figure 4.12 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Target Indication
Figure 4.13 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Directly Reprogrammed cells
Figure 4.14 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Application
Figure 4.15 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
Figure 4.16 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Geographical Location
Figure 4.17 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Technology
Figure 4.18 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Vector Used
Figure 4.19 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Source Cell for iPSC Generation
Figure 5.1 Competitiveness Analysis of iPSCs Generation Service and Product Providers
Figure 5.2 Competitiveness Analysis of Direct Reprogramming Service and Product Providers
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Trial Registration Year, 2011-2019
Figure 7.6 Clinical Trial Analysis: Distribution by Study Design
Figure 7.7 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 7.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.9 Clinical Trial Analysis: Leading Industry Players
Figure 7.10 Clinical Trial Analysis: Distribution by Focus Area
Figure 7.11 Clinical Trial Analysis: Distribution by Type of Stem Cell
Figure 7.12 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
Figure 7.13 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.14 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Figure 7.15 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
Figure 7.16 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
Figure 7.17 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
Figure 7.18 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 7.19 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Figure 7.20 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Stem Cell
Figure 8.6 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 8.7 Partnerships and Collaborations: Distribution by Application
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Regional Analysis
Figure 8.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreement
Figure 10.1 Global Cell Reprogramming Services and Products Market, 2020-2030 (USD Million)
Figure 10.2 Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, 2020-2030
Figure 10.3 Cell Reprogramming Services and Products Market for Episomal Reprogramming, 2020-2030 (USD Million)
Figure 10.4 Cell Reprogramming Services and Products Market for mRNA Reprogramming, 2020-2030 (USD Million)
Figure 10.5 Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, 2020-2030 (USD Million)
Figure 10.6 Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, 2020-2030 (USD Million)
Figure 10.7 Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, 2020-2030
Figure 10.8 Cell Reprogramming Services and Products Market for Fibroblasts, 2020-2030 (USD Million)
Figure 10.9 Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, 2020-2030 (USD Million)
Figure 10.10 Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, 2020-2030 (USD Million)
Figure 10.11 Cell Reprogramming Services and Products Market for Other Cells, 2020-2030 (USD Million)
Figure 10.12 Global Cell Reprogramming Services and Products Market: Distribution by Application, 2020-2030
Figure 10.13 Cell Reprogramming Services and Products Market for Research, 2020-2030 (USD Million)
Figure 10.14 Cell Reprogramming Services and Products Market for Therapeutic Use, 2020-2030 (USD Million)
Figure 10.15 Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, 2020-2030
Figure 10.16 Cell Reprogramming Services and Products Market in North America, 2020-2030 (USD Million)
Figure 10.17 Cell Reprogramming Services and Products Market in Europe, 2020-2030 (USD Million)
Figure 10.18 Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)

List Of Tables

Table 3.1 Differences between Stem Cell Therapies and Other Biologics
Table 4.1 Cell Reprogramming Services and Products: List of Industry Players
Table 4.2 Cell Reprogramming Services and Products: List of Non-Industry Players
Table 4.3 Cell Reprogramming Services and Products: List of Affiliated Product Providers
Table 6.1 Cell Reprogramming Service and Product Providers: List of Profiled Companies
Table 6.2 ALSTEM: Company Snapshot
Table 6.3 ALSTEM: Recent Developments and Future Outlook
Table 6.4 Applied Biological Materials: Company Snapshot
Table 6.5 Applied Biological Materials: Recent Developments and Future Outlook
Table 6.6 Axol Bioscience: Company Snapshot
Table 6.7 Axol Bioscience: Recent Developments and Future Outlook
Table 6.8 Creative Bioarray: Company Snapshot
Table 6.9 Creative Bioarray: Recent Developments and Future Outlook
Table 6.10 DefiniGEN: Company Snapshot
Table 6.11 DefiniGEN: Recent Developments and Future Outlook
Table 6.12 FUJIFILM Cellular Dynamics International: Company Snapshot
Table 6.13 FUJIFILM Cellular Dynamics International: Recent Developments and Future Outlook
Table 6.14 Lonza: Company Snapshot
Table 6.15 Lonza: Recent Developments and Future Outlook
Table 6.16 Mogrify: Company Snapshot
Table 6.17 Mogrify: Recent Developments and Future Outlook
Table 6.18 REPROCELL: Company Snapshot
Table 6.19 REPROCELL: Recent Developments and Future Outlook
Table 6.20 Stemnovate: Company Snapshot
Table 6.21 Stemnovate: Recent Developments and Future Outlook
Table 6.22 Thermo Fisher Scientific: Company Snapshot
Table 6.23 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 7.1 Cell Reprogramming Services: List of Partnerships and Collaborations
Table 9.1 Likely Partners for Cell Reprogramming Service and Product Providers in North America
Table 9.2 Likely Partners for Cell Reprogramming Service and Product Providers in Europe
Table 9.3 Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
Table 9.4 Likely Partners for Cell Reprogramming Service and Product Providers in North America
Table 9.5 Likely Partners for Cell Reprogramming Service and Product Providers in Europe
Table 9.6 Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
Table 11.1 Asgard Therapeutics: Company Snapshot
Table 11.2 Phenocell: Company Snapshot
Table 13.1 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Year of Establishment
Table 13.2 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Company Size
Table 13.3 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Geographical Location
Table 13.4 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Location of Manufacturing Facilities
Table 13.5 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Service
Table 13.6 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Offering
Table 13.7 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology
Table 13.8 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology and Year of Establishment
Table 13.9 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Vector Used
Table 13.10 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation
Table 13.11 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Source Cell for iPSC Generation and company size
Table 13.12 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Target Indication
Table 13.13 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of directly reprogrammed cell
Table 13.14 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Application
Table 13.15 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
Table 13.16 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Geographical Location
Table 13.17 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Technology
Table 13.18 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Vector Used
Table 13.19 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Source Cell for iPSC Generation
Table 13.20 Clinical Trial Analysis: Distribution by Trial Status
Table 13.21 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
Table 13.22 Clinical Trial Analysis: Distribution by Trial Phase
Table 13.23 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, 2011-2019
Table 13.24 Clinical Trial Analysis: Distribution by Study Design
Table 13.25 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 13.26 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 13.27 Clinical Trial Analysis: Leading Industry Players
Table 13.28 Clinical Trial Analysis: Analysis by Type of Stem Cell
Table 13.29 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
Table 13.30 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 13.31 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Table 13.32 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
Table 13.33 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
Table 13.34 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
Table 13.35 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 13.36 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Table 13.37 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient
Table 13.38 Partnerships and Collaborations: Analysis by Year of Partnership
Table 13.39 Partnerships and Collaborations: Analysis by Type of Partnership
Table 13.40 Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
Table 13.41 Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Table 13.42 Partnerships and Collaborations: Analysis by Type of Stem Cell
Table 13.43 Partnerships and Collaborations: Analysis by Target Therapeutic Area
Table 13.44 Partnerships and Collaborations: Analysis by Application
Table 13.45 Most Active Players: Distribution by Number of Partnerships
Table 13.46 Partnerships and Collaborations: Regional Analysis
Table 13.47 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 13.48 Global Cell Reprogramming Services and Products Market, 2020-2030 (USD Million)
Table 13.49 Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, 2020-2030
Table 13.50 Cell Reprogramming Services and Products Market for Episomal Reprogramming, 2020-2030 (USD Million)
Table 13.51 Cell Reprogramming Services and Products Market for mRNA Reprogramming, 2020-2030 (USD Million)
Table 13.52 Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, 2020-2030 (USD Million)
Table 13.53 Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, 2020-2030 (USD Million)
Table 13.54 Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, 2020-2030
Table 13.55 Cell Reprogramming Services and Products Market for Fibroblasts, 2020-2030 (USD Million)
Table 13.56 Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, 2020-2030 (USD Million)
Table 13.57 Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, 2020-2030 (USD Million)
Table 13.58 Cell Reprogramming Services and Products Market for Other Cells, 2020-2030 (USD Million)
Table 13.59 Global Cell Reprogramming Services and Products Market: Distribution by Application, 2020-2030
Table 13.60 Cell Reprogramming Services and Products Market for Research, 2020-2030 (USD Million)
Table 13.61 Cell Reprogramming Services and Products Market for Therapeutic Use, 2020-2030 (USD Million)
Table 13.62 Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, 2020-2030
Table 13.63 Cell Reprogramming Services and Products Market in North America, 2020-2030 (USD Million)
Table 13.64 Cell Reprogramming Services and Products Market in Europe, 2020-2030 (USD Million)
Table 13.65 Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3P Biopharmaceuticals
  2. AA Partners (Ilaya)
  3. Abcam
  4. ACEA Biosciences
  5. Addgene
  6. Aegle Therapeutics
  7. Allele Biotechnology
  8. Alpine BioTherapeutics
  9. ALSTEM
  10. Altaco XXI
  11. American CryoStem
  12. Amgen
  13. AMS Biotechnology
  14. Angel Biotechnology
  15. Angiocrine Bioscience
  16. Anterogen
  17. apceth Biopharma
  18. Applied Biological Materials
  19. Applied StemCell
  20. Asahi Glass
  21. Asgard Therapeutics
  22. Aspire Health Science
  23. Astellas Pharma
  24. Athersys
  25. Atlantic Bio GMP
  26. Axcelead Drug Discovery Partners
  27. Axiogenesis
  28. Axis Biotec Brasil
  29. Axol Bioscience
  30. Azidus
  31. Bayer
  32. Baylx
  33. BC Children’s Hospital Research Institute
  34. Berlin Institute of Health
  35. BHI Therapeutic Sciences
  36. Bio Elpida
  37. BioCardia
  38. Biocenter Finland
  39. BioGenCell
  40. Bioinova sro
  41. BioLamina
  42. Biological Industries
  43. Bioneer
  44. BioNTech IMFS
  45. Bioquark
  46. BioreclamationIVT
  47. BioRestorative Therapies
  48. Bit Bio
  49. Blood Reprogramming Technologies
  50. BlueRock Therapeutics
  51. Bone Therapeutics
  52. BrainStorm Cell Therapeutics
  53. Brigham and Women’s Hospital
  54. Broad Institute
  55. Bukwang Pharmaceutical
  56. Caladrius Biosciences
  57. Cancer Genetics
  58. Capricor Therapeutics
  59. CAR-T (Shanghai) Biotechnology
  60. Cedars-Sinai
  61. Celgene
  62. Celixir
  63. Cell and Gene Therapy Catapult
  64. Cell Applications
  65. Cell Reprogramming & Therapeutics
  66. Cell Signaling Technology
  67. Cell Tech Pharmed
  68. Cell Therapies
  69. Cellaria Biosciences
  70. Cellerant Therapeutics
  71. CELLforCURE
  72. CellProthera
  73. Cellular Biomedicine Group
  74. Cellular Engineering Technologies
  75. Cellular Reprogramming
  76. Censo Biotechnologies
  77. Center for iPS Cell Research and Application, Kyoto University
  78. Center for Molecular Medicine, Karolinska University Hospital
  79. Center for Regenerative Therapies, German Research Foundation
  80. CENTOGENE
  81. Cesca Therapeutics
  82. CHA Biolab
  83. Chabiotech
  84. Charles River
  85. Chiesi Farmaceutici
  86. China Regenerative Medicine International 
  87. Cincinnati Children’s Hospital Medical Center
  88. Cleans Cells
  89. Cognate BioServices
  90. Columbia Stem Cell Initiative
  91. Cook MyoSite
  92. Corestem
  93. Creative Bioarray
  94. Creative Biolabs
  95. Cryosite
  96. CureCell
  97. Cynata Therapeutics
  98. Cytopeutics
  99. DefiniGEN
  100. DiscGenics
  101. Editas Medicine
  102. EHL Bio
  103. EpiBone
  104. Escape Therapeutics
  105. ESI BIO
  106. European Bank for induced pluripotent Stem Cells
  107. European Institute for the Biology of Ageing 
  108. Ever Supreme Bio technology
  109. Evercyte
  110. Evotec
  111. Evotec
  112. Fate Therapeutics
  113. Feinberg School of Medicine
  114. Ferrer Internacional
  115. Fibrocell Science
  116. Fortuna Fix
  117. FUJIFILM Cellular Dynamics
  118. Gamida Cell
  119. GE Healthcare
  120. GenCure
  121. GeneCopoeia
  122. Genenta Science
  123. Genome Engineering and iPSC Center 
  124. German Stem Cell Research Network
  125. GlaxoSmithKline
  126. Global Cell Med
  127. Gwo xi Stem Cell
  128. Harvard Stem Cell Institute
  129. Harvard University Stem Cell Institute
  130. Hemogenyx
  131. Hemostemix
  132. Histocell
  133. Hitachi Chemical
  134. Hope Biosciences
  135. Hubei Hongyuan Pharmaceutical technology
  136. Human Pluripotent Stem Cell Core Facility
  137. Icahn School of Medicine
  138. ID Pharma
  139. Indiana University
  140. Indiana University Research and Technology
  141. InSphero
  142. Institute of Molecular Biotechnology (IMBA)
  143. Institute of Molecular Biotechnology, Austrian Academy of Sceinces
  144. International Stem Cell Corporation
  145. iPS Academia Japan
  146. iXCells Biotechnologies
  147. Japan Regenerative Medicine
  148. Japan Tissue Engineering
  149. Japan Tissue Engineering (J-TEC)
  150. jCyte
  151. Kadimastem
  152. Kangstem Biotech
  153. KBI Biopharma
  154. Kemwell Biopharma
  155. KLSMC Stem Cells
  156. K-Stem Cell
  157. LAI International
  158. Leiden University Medical Center
  159. Life & Brain
  160. LifeCell
  161. Lineage Cell Therapeutics
  162. Longeveron
  163. Lonza
  164. Magellan Stem Cells
  165. Magenta Therapeutics
  166. MangoGen Pharma
  167. MaSTherCell
  168. McEwen Stem Cell Institute
  169. Med Cell Bahamas
  170. Medeor Therapeutics
  171. Medicines Discovery Catapult
  172. MEDINET
  173. Medipost
  174. Melbourne Stem Cell Centre
  175. Memorial Sloan Kettering Cancer Center 
  176. Merck
  177. Meridigen Biotech
  178. Mesoblast
  179. Metrion Biosciences
  180. MilliporeSigma
  181. Miltenyi Biotec
  182. Minovia Therapeutics
  183. Mogrify
  184. National Eye Institute
  185. Nature Cell
  186. Ncardia
  187. Ncardia 
  188. NeuCyte
  189. NeuroGeneration
  190. New York Blood Center
  191. Newcastle University
  192. Newcells Biotech
  193. NextCell Pharma
  194. Nikon CeLL innovation
  195. Nipro
  196. Nohla Therapeutics
  197. Noray Biosciences Group
  198. Novadip Biosciences
  199. Novartis Pharmaceuticals
  200. NuVasive
  201. ONO Pharmaceutical 
  202. Orchard Therapeutics
  203. Orgenesis
  204. Orthofix
  205. Osiris Therapeutics
  206. Oslo University Hospital
  207. Ottawa Hospital Research Institute
  208. Penn's Institute for Regenerative Medicine
  209. Personalized Stem Cells
  210. Pharmicell
  211. Phenocell
  212. Pluriomics
  213. Pluristem Therapeutics
  214. Plus Therapeutics
  215. Promethera Biosciences
  216. Propagenix
  217. Protide Pharmaceuticals
  218. Provia Labs
  219. Q Therapeutics
  220. R3 Stem Cell
  221. Radboudumc Stem Cell Technology Center
  222. R-Bio
  223. Regeneus
  224. Regenexx
  225. Reliance Life Sciences
  226. ReNeuron
  227. ReproCell
  228. RheinCell Therapeutics
  229. Riordan Technologies
  230. Rockland Immunochemicals
  231. ROHTO Pharmaceutical
  232. Roslin Cells
  233. RTI Surgical
  234. S.Biomedics 
  235. Salvat
  236. Samsung BioLogics
  237. SanBio
  238. Sanofi
  239. Sanquin
  240. SBH Sciences
  241. Sclnow Biotechnology 
  242. SCM Lifescience
  243. SCM Lifescience
  244. Seneca Biopharma
  245. Sentien Biotechnologies
  246. Shandong Qilu Stem Cells Engineering
  247. Shenzhen Hornetcorn Biotechnology
  248. Stem Cell Medicine
  249. Stem Med
  250. STEMCELL Technologies
  251. StemCore
  252. Stemedica Cell Technologies
  253. Stemgenics
  254. Steminent Biotherapeutics
  255. Stemmatters 
  256. Stemnovate
  257. Stempeutics Research
  258. Stryker
  259. Swiss Medica XXI Century
  260. System Bioscience
  261. Taiwan Bio Therapeutics
  262. Taiwan Human Disease iPSC Consortium
  263. Takara Bio
  264. Takara Bio
  265. Takeda
  266. Talaris Therapeutics
  267. Terumo
  268. The Emmes Company
  269. The University of California, Irvine
  270. The University California, San Diego
  271. The University Hospital of Dusseldorf 
  272. The University of Wisconsin
  273. Thermo Fisher Scientific
  274. Tianhe Stem Cell Biotechnologies
  275. Tianjin Ever Union Biotechnology 
  276. Tianjin Weikai Biological Engineering
  277. TICEBA
  278. Tocris Bioscience
  279. TreeFrog Therapeutics
  280. Turn Biotechnologies
  281. U.S. Stem Cell
  282. United Therapeutics
  283. Universal Cells
  284. University Medical Center Göttingen
  285. University of Bonn
  286. University of Cambridge
  287. University of Colorado
  288. University of Florida College of Medicine
  289. University of Helsinki
  290. University of Texas
  291. University of Utah
  292. University of Washington’s Institute for Stem Cell and Regenerative Medicine 
  293. University at Buffalo
  294. VcanBio Center for Translational Biotechnology
  295. Vericel
  296. VetStem
  297. ViaCyte
  298. Viscofan BioEngineering
  299. Waisman Biomanufacturing
  300. WuXi Advanced Therapies
  301. Yale Stem Cell Center
  302. YposKesi

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com